June 1, 2023
Abilita Bio changes name to Abilita Therapeutics and appoints Joel Edwards as chief business officer

Name change to Abilita Therapeutics reflects the company’s focus and newly established capabilities to build an internal pipeline of first- and best-in-class therapeutics.

Abilita Therapeutics strengthens leadership team by appointing Joel Edwards as chief business officer to advance corporate strategy and partnering efforts.


Full Press Release
Press Release direct link
May 9, 2023
Abilita Bio to showcase Enabled Membrane Protein technologies at PEGS Boston conference

On the heels of a $7.5m financing round, the company will present its breakthrough platform technologies that are empowering the development of membrane protein-targeted treatments.

Full Press Release
February 21, 2023
Abilita Bio secures $7.5 million in equity financing from Two Bear Capital

Funding will Propel Abilita Bio’s Preclinical Therapeutic Programs and Accelerate the Company’s Overall Growth.

Full Press Release
Press Release direct link
March 23, 2022
Abilita Bio selected as one of San Diego’s ‘Cool Companies’ 2022

Abilita Bio will also participate as a ‘Cool Company’ to the first ‘San Diego Innovation Day’ event, organized by CONNECT on April 28 at Petko Park, San Diego.

Link to the event
Link to the ‘Cool Company’ site
February 23, 2022
Abilita Bio Appoints Dan Bradbury to its Newly Formed Board of Directors

Abilita Bio, Inc., today announced the appointment of Daniel M. Bradbury to its Board of Directors. Mr. Bradbury is a seasoned biotech executive and business strategist with a formidable track record of building successful biotech companies. His guidance will be key to growing the leadership team, crafting our approach, and building a solid clinical development plan.

Full press release
PR Newswire link
August 24, 2021
Abveris and Abilita Bio Announce a Discovery Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets
The research collaboration will leverage synergies between the Abilita Bio EMP™ and Abveris DiversimAb™ platforms to identify novel therapeutic antibodies that target historically intractable GPCRs for the treatment of cancer
January 9, 2020
Abilita Bio Announces Business Growth and Key Developments
Shift to discovery of proprietary programs facilitated by increased resources, infrastructure and capabilities
Abilita Bio, Inc. today announced a series of corporate updates that includes an expansion of scientific scope, personnel, and infrastructure.
Full press release
GlobeNewswire link
May 20, 2019
Tom Boone joins Abilita Bio’s Scientific Advisory Board
Abilita Bio today announced the appointment of Tom Boone, a world-renowned expert in biologics discovery and development, to their Scientific Advisory Board.
Full Release
June 3-6, 2019
Abilita Bio will be an exhibitor at the 2019 BIO Convention in Philadelphia
Abilita Bio will be participating in the BIO Convention exhibition and One-on-One Partnering™ program, taking place at the Pennsylvania Convention Center in Philadelphia, PA. Meet with us at our exhibit kiosk IZ-21 within the NIH Innovation Zone (Booth #4270).

Full Poster
February 13, 2019
Abilita Bio and Amgen Enter Into a Multi-Target Collaboration
Abilita Bio, Inc., announced today that it has entered into a multi-target research collaboration agreement with Amgen, Inc. (AMGN), a world leader in biotechnology. Under the terms of the agreement, Abilita Bio will leverage its proprietary Enabled Membrane Protein (EMP™) technology platform to support Amgen’s R&D efforts on challenging integral membrane protein targets.
Full press release
PRNewswire link
September 1, 2018
Abilita Bio Awarded NIH Phase-I SBIR Grant to Discover Non-Opioid Pain Therapeutics
Abilita Bio, Inc., announced the award of a Phase I SBIR Grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to fund the discovery of novel biologic agents that target human voltage-gated sodium (NaV) channels for the non-opioid treatment of pain.
Full press release
December 13, 2017
X-Chem and Abilita Bio Announce a Joint Research Collaboration
X-Chem, Inc. and Abilita Bio, Inc., both privately held biotechnology companies, announced today a joint research collaboration that will leverage the synergy between each company’s platform technology to enable the discovery of novel modulators of high-value G-protein coupled receptors (GPCRs) and ion channel targets.
Full press release
Businesswire link
October 17, 2017
Abilita Bio’s CEO Mauro Mileni is presenting at the BIO Investment Forum 2017 in San Francisco.
Abilita Bio’s CEO Mauro Mileni is presenting at the BIO Investment Forum 2017 in San Francisco. Come hear our latest accomplishments. The presentation will be at 9:45am in the Yorkshire Room.
October 11, 2017
Abilita Bio Announces the Appointment of Charlie Rodi, PhD to the Executive Advisory Board
Abilita Bio, Inc. today announced the appointment of Dr. Charlie Rodi to the company’s Executive Advisory Board. For more information about Dr. Rodi please follow the link below.
Executive Advisory Board Page
June 19-22, 2017
Abilita Bio will be participating in the BIO One-on-One Partnering program in its home town San Diego, CA
January 30, 2017
Abilita Bio Signs a New Research Collaboration with a Global Pharmaceutical Company and 2016 Milestone Review
Abilita Bio, Inc. announced today a second research collaboration agreement with a major pharmaceutical partner, which will leverage Abilita Bio’s proprietary EMP™ membrane protein evolution platform to accelerate G protein-coupled receptor (GPCR) drug discovery and development.
Full press release
Businesswire link
January 9-11, 2017
Abilita Bio will be participating in the Biotech Showcase Partnering program in San Francisco, CA
September 20, 2016
Abilita Bio, Inc. Awarded NCI Phase-I SBIR Grant to Develop Therapeutic Antibodies Targeting Metastatic Breast Cancer
Abilita Bio, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to develop therapeutic antibodies targeting G Protein-Coupled Receptors (GPCRs) involved in the metastasis of breast cancer, including prostaglandin E2 receptor 2 (EP2), prostaglandin E2 receptor 4 (EP4), and C-C chemokine receptor 7 (CCR7).
Full press release
July 12, 2016
Abilita Bio’s CEO Mauro Mileni speaks at the San Diego Entrepreneurs Exchange (SDEE) Founder’s Tales Event
Come hear the story of the founding of Abilita Bio at the SDEE’s famous event Founder’s Tales.
June 6-9, 2016
Abilita Bio will be participating in the BIO One-on-One Partnering™ program, taking place at the Moscone Center in San Francisco, CA. We hope to see you there!
April 12, 2016
Abilita Bio Appoints Christopher B. Roth, PhD to Vice President, Innovation
Abilita Bio, Inc. announced today that Christopher B. Roth has been appointed to the role of Vice President, Innovation. In conjunction with this appointment, Dr. Roth will step down as a member of Abilita Bio’s Scientific Advisory Board, which he joined in 2015.
Full press release
December 14, 2015
Primordial Genetics and Abilita Bio Establish Collaboration to Produce Stabilized G Protein-Coupled Receptors (GPCRs) in Bacteria
Abilita Bio Inc. and Primordial Genetics Inc., a biotechnology company that provides genetic solutions for improvement of production microbes, have signed a collaboration agreement for use of Primordial Genetics’ Function Generator™ genetic improvement technology to develop advanced strains of E. coli for expression of mammalian membrane proteins that have been optimized for structural and drug development efforts using Abilita’s proprietary Enabled Membrane Proteins (EMPs™) technology. To learn more about Primordial Genetics, please see www.primordialgenetics.com
Full press release
June 17, 2015
Abilita Bio, Inc. is proud to announce the addition of Laura Solforosi to our Scientific Advisory Board
Laura Solforosi, PhD: Antibodies & Vaccines
Senior Scientist at Janssen Infectious Disease and Vaccine
June 9, 2015
Abilita Bio, Inc. is pleased to announce the addition of Dr. Alexander Alexandrov as Principal Scientist
June 4, 2015
Abilita Bio, Inc. is proud to announce the formation of our Scientific Advisory Board
Sandro Cosconati, PhD: Computational Chemistry
Assistant Professor of Medicinal Chemistry, Second University of Naples
Tracy Handel, PhD: Pharmacology
Professor of Pharmacy, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences Department of Pharmacology
Wei Liu, PhD: Crystallography
Assistant Professor, Arizona State University Department of Chemistry & Biochemistry and The Biodesign Institute, Applied Structural Discovery
Fred Ramsdell, PhD: Immunology
Vice President, Immunology at aTyr Pharma
Chris Roth, PhD: Protein Engineering
Biotech Industry Consultant